27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Understanding the lifetime risk of dementia can inform public health planning and improve patient engagement in prevention. 1 key finding →
Design: cohort Participants: 15,043 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Evidence suggests that delirium is associated with long-term poor outcome but delirium often occurs in individuals with more severe underlying disease. 5 key findings →
Design: meta-analysis Participants: 714 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The incidence rate of dementia in Europe and North America has declined by 13% per decade over the past 25 years, consistently across studies. 2 key findings →
Design: cohort study Participants: 49,202 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the estrogen-alone trial, 47 participants were diagnosed with probable dementia, of whom 28 were assigned to CEE and 19 to placebo (hazard ratio [HR], 1.49; 95% confidence interval [CI], 0.83-2.66). 3 key findings →
Participants: 4,532 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Older people with SMC but no objective complaints are twice as likely to develop dementia as individuals without SMC. 3 key findings →
Design: meta-analysis Participants: 15,009 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
For women aged 65 years or older, hormone therapy had an adverse effect on cognition, which was greater among women with lower cognitive function at initiation of treatment. 1 key finding →
Participants: 1,387 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence from well-planned, representative epidemiological surveys is scarce in many regions. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A nurse-led, multidomain intervention did not result in a reduced incidence of all-cause dementia in an unselected population of older people. 3 key findings →
Design: randomized controlled trial Participants: 3,526 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Higher all-cause mortality was observed among apparently healthy older adults who received daily aspirin than among those who received placebo and was attributed primarily to cancer-related death. 3 key findings →
Participants: 19,114 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia and MCI are associated with neuropsychiatric symptoms in clinical samples. 4 key findings →
Design: cohort study Participants: 138 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Frontotemporal dementia (FTD) is a complex disorder characterised by a broad range of clinical manifestations, differential pathological signatures, and genetic variability. 4 key findings →
Design: meta-analysis Participants: 3,526 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The most common anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and bladder antimuscarinics. 4 key findings →
Design: cohort study Participants: 3,434 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Leisure-time physical activity at midlife at least twice a week was associated with a reduced risk of dementia and AD (odds ratio [OR] 0.48 [95% CI 0.25-0.91] and 0.38 [0.17-0.85], respectively), even after adjustments for age, sex, education, follow-up time, locomotor disorders, APOE genotype, vascular disorders, smoking, and alcohol drinking. 2 key findings →
Participants: 1,449 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Substantial variation in the prevalence of dementia in Parkinson's disease (PDD) has been reported. 2 key findings →
Design: systematic review Participants: 1,767 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 95 unique studies were included in this systematic review, of which 74 with 2 760 379 unique patients were also included in 5-year age band meta-analyses. 5 key findings →
Design: systematic review Participants: 95 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The presence of multiple cardiovascular risk factors at midlife substantially increases risk of late-life dementia in a dose dependent manner. 5 key findings →
Design: cohort study Participants: 8,845 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This large meta-analysis pooled dozens of studies to estimate how many people under age 65 are living with dementia worldwide. 4 key findings →
Design: meta-analysis Participants: 2,760,379 Evidence: moderate
Full summary, score breakdown and related studies → Original source
After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. 2 key findings →
Design: cohort study Participants: 94 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 275 patients, 51 (18.5%) had persistent coma and died in the hospital. 2 key findings →
Design: cohort study Participants: 275 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia. 3 key findings →
Design: cohort study Participants: 6,989 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher Hcy levels, lower educational attainment, and decreased physical activity were particularly strong predictors of incident AD. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
MCR is common in older adults, and is a strong and early risk factor for cognitive decline. 3 key findings →
Design: cohort study Participants: 26,802 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The average life expectancy of people with dementia at time of diagnosis ranged from 5.7 years at age 65 to 2.2 at age 85 in men and from 8.0 to 4.5, respectively, in women. 5 key findings →
Design: meta-analysis Participants: 5,553,960 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The relation between diabetes and major types of dementia is controversial. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up. 5 key findings →
Participants: 1,280 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →